ABSTRACT
The Food and Drug Administration (FDA) Critical Path Initiative as well as the European Medicines Agency Road Map to 2010 (ref. 2) call for opportunities for more efficient drug development. One of the initiatives that has emerged in this context is the elaboration through guidance of exploratory investigational new drugs (INDs)/clinical trial applications (CTAs). This article reviews the history of these emerging guidances as well as the experience to date in their use by the industry.
Subject(s)
Clinical Trials, Phase I as Topic , Drug Industry , Drugs, Investigational/administration & dosage , Investigational New Drug Application , Animals , Clinical Trials, Phase I as Topic/legislation & jurisprudence , Dose-Response Relationship, Drug , Drug Administration Routes , Drug Industry/legislation & jurisprudence , Drugs, Investigational/pharmacokinetics , Drugs, Investigational/toxicity , Europe , Guidelines as Topic , Humans , Investigational New Drug Application/legislation & jurisprudence , Models, Biological , No-Observed-Adverse-Effect Level , Program Development , United States , United States Food and Drug AdministrationABSTRACT
Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, was metabolized by human liver microsomes to 5-hydroxy-, 6-hydroxy-, and N-deisopropyl-fluvastatin. Total metabolite formation was biphasic with apparent Km values of 0.2 to 0.7 and 7.9 to 50 microM and intrinsic metabolic clearance rates of 1.4 to 4 and 0.3 to 1.5 ml/h/mg microsomal protein for the high and low Km components, respectively. Several enzymes, but mainly CYP2C9, catalyzed fluvastatin metabolism. Only CYP2C9 inhibitors such as sulfaphenazole inhibited the formation of both 6-hydroxy- and N-deisopropyl-fluvastatin. 5-Hydroxy-fluvastatin formation was reduced by compounds that are inhibitors of CYP2C9, CYP3A, or CYP2C8. Fluvastatin in turn inhibited CYP2C9-catalyzed tolbutamide and diclofenac hydroxylation with Ki values of 0.3 and 0.5 microM, respectively. For CYP2C8-catalyzed 6alpha-hydroxy-paclitaxel formation the IC50 was 20 microM and for CYP1A2, CYP2C19, and CYP3A catalyzed reactions, no IC50 could be determined up to 100 microM fluvastatin. All three fluvastatin metabolites were also formed by recombinant CYP2C9, whereas CYP1A1, CYP2C8, CYP2D6, and CYP3A4 produced only 5-hydroxy-fluvastatin. Km values were approximately 1, 2.8, and 7.1 microM for CYP2C9, CYP2C8, and CYP3A, respectively. No difference in fluvastatin metabolism was found between the CYP2C9R144 and CYP2C9C144 alleles, suggesting the absence of polymorphic fluvastatin metabolism by these alleles. CYP1A2, CYP2A6, CYP2B6, CYP2C19, CYP2E1, and CYP3A5 did not produce detectable amounts of any metabolite. This data indicates that several human cytochrome P-450 enzymes metabolize fluvastatin with CYP2C9 contributing 50-80%. Any coadministered drug would therefore only partially reduce the metabolic clearance of fluvastatin; therefore, the likelihood for serious metabolic drug interactions is expected to be minimal.
Subject(s)
Cytochrome P-450 Enzyme Inhibitors , Cytochrome P-450 Enzyme System/metabolism , Fatty Acids, Monounsaturated/pharmacology , Fatty Acids, Monounsaturated/pharmacokinetics , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacokinetics , Indoles/pharmacology , Indoles/pharmacokinetics , Biotransformation , Drug Interactions , Fatty Acids, Monounsaturated/metabolism , Fluvastatin , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/metabolism , Indoles/metabolism , Isoenzymes/antagonists & inhibitors , Isoenzymes/metabolism , KineticsSubject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/antagonists & inhibitors , Aryl Hydrocarbon Hydroxylases , Cyclosporine/pharmacokinetics , Cytochrome P-450 Enzyme Inhibitors , Immunosuppressive Agents/pharmacokinetics , Oxidoreductases, N-Demethylating/antagonists & inhibitors , Administration, Oral , Biological Availability , Biotransformation , Cross-Over Studies , Cyclosporine/administration & dosage , Cyclosporine/blood , Cytochrome P-450 CYP3A , Dosage Forms , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/blood , Male , Metabolic Clearance Rate/drug effects , Protein Synthesis Inhibitors/pharmacologyABSTRACT
The structure, stereochemistry, and conformation of theonellapeptolide IIIe (1), a new 36-membered ring cyclic peptolide from the New Zealand deep-water sponge Lamellomorpha strongylata, is described. The sequence of the cytotoxic peptolide was determined through a combination of NMR and MS-MS techniques and confirmed by X-ray crystal structure analysis, which, with chiral HPLC, established the absolute stereochemistry.
Subject(s)
Antineoplastic Agents/isolation & purification , Peptides, Cyclic/isolation & purification , Porifera/chemistry , Amino Acids/analysis , Animals , Antineoplastic Agents/pharmacology , Gas Chromatography-Mass Spectrometry , New Zealand , Peptides, Cyclic/pharmacology , Protein Conformation , Spectrometry, Mass, Fast Atom Bombardment , X-Ray DiffractionABSTRACT
OBJECTIVE: To characterize the pharmacokinetics of a single 5 mg oral dose of abecarnil in subjects with varying degrees of renal impairment. METHODS: Twenty-six subjects were enrolled in this open-label parallel-group study. Ten subjects had normal renal function (NRF; creatinine clearance [CLCR] > or = 85 ml/min/1.73 m2), six subjects had mild to moderate renal insufficiency (MMRI; CLCR between 25 and 73 ml/min/1.73 m2), and 10 subjects had severe renal insufficiency (SRI; CLCR < or = 10 ml/min/1.73 m2). Abecarnil plasma concentrations were determined by means of HPLC, and plasma protein binding was determined by use of ultracentrifugation. Pharmacokinetic parameters were obtained with use of model-independent and model-dependent methods. RESULTS: In subjects with SRI, area under the concentration-time curve and maximum plasma concentration were reduced by 36% and 31%, respectively, compared with demographically matched subjects with NRF. The apparent total body clearance in the NRF, MMRI, and SRI groups was 13.0 +/- 6.89, 12.9 +/- 3.64, and 25.0 +/- 13 ml/min/kg, and the apparent volume of distribution was 14.0 +/- 3.78, 12.8 +/- 2.4, and 19.4 +/- 5.76 L/kg, respectively (mean +/- SD). The patients with SRI had a significantly lower protein bound fraction than subjects with NRF (0.850 +/- 0.077 versus 0.948 +/- 0.023). Despite an increase in the free fraction of abecarnil (f(u)), there was no significant change in the apparent unbound total body clearance and unbound volume of distribution between the SRI and NRF groups. The anticipated full effect of the increase in f(u) among the patients with SRI was not realized and suggests that the f(u) in tissue may be increased in patients with SRI. CONCLUSION: Dose adjustment will need to be made on the basis of titration to the desired clinical response and tolerability in patients with SRI just as in subjects with NRF.
Subject(s)
Anti-Anxiety Agents/pharmacokinetics , Carbolines/pharmacokinetics , Renal Insufficiency/metabolism , Administration, Oral , Adult , Aged , Anti-Anxiety Agents/administration & dosage , Black People , Blood Proteins/metabolism , Carbolines/administration & dosage , Carbolines/blood , Carbolines/urine , Chromatography, High Pressure Liquid , Creatinine/urine , Dose-Response Relationship, Drug , Female , Humans , Kidney Function Tests , Male , Middle Aged , Protein Binding , Regression Analysis , White PeopleABSTRACT
A nonlinear mixed-effects model simultaneously modeled two pharmacokinetic (PK) variables in patients administered cyclosporine twice daily: (i) concentration of drug in blood at the end of the 12-hr dosing interval (C12) and (ii) area under the concentration-time curve within the dosing interval (AUC). For two formulations (Neoral and Sandimmune), the model assessed the following: nonlinearity with respect to dose, interoccasion (intraindividual) variability, interindividual variability, and within- and across-individual correlation between C12 and AUC. Data were pooled from six clinical studies in stable renal transplant patients administered each formulation. PK samples on two occasions were taken usually for each formulation. Each individual's random effect was eight-dimensional consisting of two PK variables for each formulation on two occasions. An ANOVA-like partitioning worked well and reduced the variance matrix for the random effect to a known function of 13 parameters to be estimated, thereby making a numerically intensive computation feasible. Simulations were used to check the model fit, to compute standard errors, and to account for peculiarities in the residual analysis. Outcomes of tests comparing formulations, most of which were statistically significant, favored Neoral (dose proportional, lower interoccasion variability, lower interindividual variability, and higher correlation between C12 and AUC).
Subject(s)
Computer Simulation , Cyclosporine/pharmacokinetics , Kidney Transplantation , Nonlinear Dynamics , Dosage Forms , HumansABSTRACT
To infer patterns of average systemic exposure and to estimate individual exposures in phase III clinical trials of a new anxiolytic, two statistical methodologies were applied and compared: non-linear mixed-effect modelling, and a model-free approach based on quartiles of dose-normalized plasma concentrations of the drug. Although the model-based approach provides more quantitative insight about relationships between average exposure and demographic covariates, the model-free approach provides qualitatively similar results about average clearance and quantitatively similar results about individual exposures, and the model-free approach is easy and inexpensive to implement.
Subject(s)
Anti-Anxiety Agents/blood , Anti-Anxiety Agents/pharmacokinetics , Carbolines/pharmacokinetics , Data Interpretation, Statistical , Drug Evaluation/statistics & numerical data , Models, Statistical , Adult , Age Factors , Analysis of Variance , Carbolines/blood , Clinical Trials, Phase I as Topic/statistics & numerical data , Clinical Trials, Phase III as Topic/statistics & numerical data , Dose-Response Relationship, Drug , Female , Humans , Male , Metabolic Clearance Rate , Normal Distribution , Sex Factors , Smoking/adverse effects , Statistics, NonparametricSubject(s)
Carbon Radioisotopes , Drug Industry/trends , Legislation, Drug/trends , Tritium , Adolescent , Adult , Female , Humans , Male , United States , United States Food and Drug AdministrationABSTRACT
Fluvastatin sodium (Lescol) is the first synthetic 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)-reductase inhibitor to be studied extensively in humans. Absorption of fluvastatin is complete and unaffected by the presence of food. Systemic exposure is limited because of extensive sequestration by the liver and/or first-pass metabolism, a plasma half-life of approximately 30 min, no circulating active metabolites, and no accumulation of drug during chronic dosing. Approximately 95% of a single dose of fluvastatin is excreted via the biliary route with less than 2% as the parent compound. Studies investigating the effect of food on fluvastatin pharmacokinetics have demonstrated marked reductions in the rate of bioavailability (Cmax) of 40% to 60%. A comparison of drug administration with the evening meal or at bedtime revealed no significant differences in either the extent of bioavailability (area under the curve; AUC) or pharmacodynamic effect [reduction in low-density lipoprotein cholesterol (LDL-C)]. Relative to the general population, plasma fluvastatin concentrations do not vary as a function of either age or gender. Administration of a single 40-mg dose to a patient population with hepatic insufficiency resulted in a 2.5-fold increase in both AUC and Cmax. Drug interaction studies with fluvastatin and cholestyramine (CME) demonstrated a lower rate and extent of fluvastatin bioavailability; no impact on efficacy was demonstrated when CME was given 4 h before fluvastatin dosing in clinical trials. Interaction studies with niacin and propranolol demonstrated no effects on fluvastatin plasma levels, and fluvastatin administered to a patient population chronically receiving digoxin had no effect on the AUC of digoxin compared with controls.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Cholestyramine Resin/pharmacokinetics , Fatty Acids, Monounsaturated/pharmacokinetics , Hydroxymethylglutaryl-CoA Reductase Inhibitors , Indoles/pharmacokinetics , Propranolol/pharmacokinetics , Adolescent , Adult , Aged , Aging/metabolism , Aging/physiology , Biological Availability , Cholestyramine Resin/analysis , Diet , Digoxin/blood , Digoxin/pharmacokinetics , Dose-Response Relationship, Drug , Double-Blind Method , Drug Interactions , Fatty Acids, Monounsaturated/blood , Female , Fluvastatin , Humans , Hypercholesterolemia/blood , Indoles/blood , Lipoproteins, LDL/blood , Male , Middle Aged , Niacin/blood , Niacin/pharmacokinetics , Propranolol/blood , Sex Characteristics , Time Factors , Triglycerides/bloodABSTRACT
Clozapine plasma levels were monitored in 16 patients during a series of three consecutive treatments (single dose-multiple dose-single dose). Each patient received a single 75-mg dose (3 x 25 mg) with clozapine tablets, and serial plasma samples were collected over 48 hr after the dose. At 48 hr, a multiple-dose regimen was started, consisting of an initial dose escalation period followed by dosing at a constant regimen for at least 6 days. After the last dose, serial plasma samples were again obtained over 72 hr. Drug was then withheld for at least 7 days, a final single 75-mg dose was given, and plasma sampling was repeated. A subset of the patient population (N = 7) was used to test for a food effect during the single-dose treatments. The pharmacokinetic parameters between the initial and the final single dose periods were not significantly different. Similarly, there were no differences within patients when given the dose after fasting (fed 1 hr after dose) or with a meal. In contrast, the terminal elimination rate differed between the single-dose and the multiple-dose treatments (t1/2 m3 = 7.9 hr single dose and 14.2 hr multiple dose) (P less than 0.05) and the dose-normalized area under the plasma concentration/time curves increased 27% with multiple dosing. Since a previous study in patients (Choc et al., Pharm. Res. 4:402-405, 1987) showed dose proportionality of clozapine plasma concentrations during multiple-dose regimens, the present results cannot be described by Michaelis-Menten kinetics.
Subject(s)
Clozapine/pharmacokinetics , Dibenzazepines/pharmacokinetics , Schizophrenia/metabolism , Adult , Biological Availability , Clozapine/administration & dosage , Food , Half-Life , Humans , Male , Middle Aged , Multicenter Studies as Topic , Random AllocationABSTRACT
Dose proportionality in some pharmacokinetic parameters for thioridazine and its two active metabolites (mesoridazine and sulforidazine) was investigated in 11 healthy human subjects following oral administration of three single doses (25, 50, and 100 mg) of thioridazine hydrochloride separated in each case by an interval of two weeks. Also, after a further two weeks, another 100-mg dose of thioridazine (divided as 5 mg every 0.5 h) was administered to all the volunteers to investigate the effect of a slow rate of dosage input on the pharmacokinetic parameters of this drug. An HPLC method was used to measure concentrations of thioridazine, mesoridazine, and sulforidazine in plasma samples collected up to 72 h following each dose. Dose proportionality for the three single doses of thioridazine was observed for all three analytes in the area under the plasma concentration versus time curves (AUC infinity 0 or AUCt0) and the maximum plasma concentration (Cmax) in that the relationships between the dose and these parameters were each describable by an equation for a straight line (r2 greater than or equal to 0.8). However, the mean apparent distribution and elimination rate constants for thioridazine and mesoridazine and the mean apparent oral clearance for thioridazine decreased significantly with increasing dose. This suggests nonlinear trends in the elimination kinetics at high doses of thioridazine. When a 100-mg divided oral dose of thioridazine was administered, no statistically significant differences between single and divided doses were observed in the mean AUC infinity 0 or AUCt0 for thioridazine or sulforidazine. A significant decrease in the mean AUC infinity 0 or AUCt0 was observed for mesoridazine after the administration of the divided dose.(ABSTRACT TRUNCATED AT 250 WORDS)
Subject(s)
Thioridazine/pharmacokinetics , Adult , Chromatography, High Pressure Liquid , Humans , Male , Mesoridazine/blood , Phenothiazines/blood , Thioridazine/administration & dosage , Thioridazine/metabolismABSTRACT
Thioridazine has two major active metabolites, which are formed from S-oxidation of its 2-methylthio group; the sulphoxide, mesoridazine, and the sulphone, sulforidazine. Dose proportionality of the three compounds was investigated for the first time in 11 males after administration of three single oral doses (25, 50, and 100 mg) of thioridazine hydrochloride separated in each case by two weeks. Based on the plasma concentrations of the three analytes over 72 h following each dose, large intersubject variabilities in such parameters as AUCot and Cmax were observed for each of the three compounds. The relationships between dose and parameters such as AUCot and Cmax for each analyte were described by an equation for a straight line (r2 greater than or equal to 0.8). However, the mean apparent distribution and elimination rate constants for thioridazine and mesoridazine and the mean apparent oral clearance for thioridazine decreased significantly with increasing dose, suggesting non-linearity in the elimination of thioridazine at high dose.
Subject(s)
Psychotropic Drugs/metabolism , Thioridazine/metabolism , Adult , Dose-Response Relationship, Drug , Half-Life , Humans , Male , Mesoridazine/pharmacokinetics , Oxidation-Reduction , Phenothiazines/pharmacokinetics , Thioridazine/pharmacokineticsABSTRACT
A sensitive, semi-automated high-performance liquid chromatographic method utilizing column switching is described for the determination of cyclosporine in plasma and blood. This method involves a short and improved manual protein precipitation of the sample followed by an automated clean-up of the supernatant. After automatic loading of the clean supernatant onto an LC-8 column for initial separation, the segment containing cyclosporine is loaded (automatically) onto an LC-18 column for final separation and quantitation. Cyclosporine is detected by its ultraviolet absorption at 202 nm. The rate of analysis was four samples per h running 24 h per day (ca. 100 samples per day). The method is sensitive enough to measure with confidence cyclosporine concentrations of 8 microgram/l in plasma and 20 microgram/l in blood with a linear response up to 2500 microgram/l using only 0.5 ml of sample. No internal standard is required. The method was applied continuously (24 h per day) to approximately 1000 samples without deterioration in method parameters.
Subject(s)
Cyclosporins/blood , Chromatography, High Pressure Liquid/methods , Humans , Plasma/analysis , Specimen Handling , Time FactorsABSTRACT
Upon administration of the nonsteroidal anti-inflammatory agent furobufen to mice, rats, dogs, and man, 2-dibenzofuranacetic acid (DBFA) was rapidly formed and was the major circulating metabolite. There was a species difference in the rate of DBFA formation; the serum elimination half-lives (t1/2) of furobufen and DBFA were 25 min and 6 hr in rats, 35 min and 15 hr in dogs, and 3 hr and approximately 20 hr in man, respectively. After oral and intravenous administration of 14C-furobufen to rats and dogs, virtually all of the serum radioactivity was due to furobufen and DBFA. Serum levels of DBFA in rats, dogs, and man increased in proportion to the oral dose. The t1/2 of furobufen and DBFA in man did not appear to be altered by chronic treatment and were the same in both sexes. Furobufen and DBFA were strongly bound to human serum protein (greater than 99%). A method was elaborated to measure serum furobufen and DBFA spectrophotofluorometrically in the presence of salicylates. Serum levels of furobufen and DBFA were lower in rats treated with aspirin; the effect was dependent upon the dose of aspirin. At the doses used, aspirin did not affect serum furobufen and DBFA in dogs and man.